Roche AG is pumping up its central nervous system (CNS) pipeline with the acquisition of a rare disease program from PTC Therapeutics Inc., of South Plainsfield, N.J. Read More
Making risk evaluation and mitigation strategies (REMS), especially those with elements to assure safe use (ETASU), more effective and less burdensome is a tall order. So the FDA is turning to the experts for advice on assessing those REMS. Read More
Genetic alterations that have opposing effects on neural activity can lead to disorders that superficially look very similar, and lead to similar behavioral issues. Read More
NuCana BioMed Ltd. raised £6.74 million (US$10.5 million) in a Series A round to advance a series of modified nucleoside analogues in cancer indications and has set its sights on becoming the Inhibitex Inc. or even the Pharmasset Inc. of the cancer world. Read More
• Civitas Therapeutics Inc., of Chelsea, Mass., received a grant from The Michael J. Fox Foundation for Parkinson's Research to support clinical development of its lead Parkinson's disease candidate CVT-301, an inhaled formulation of levodopa (L-dopa). Privately held Civitas did not disclose the funding amount, but said it would support studies of CVT-301 through proof of concept, expected to conclude by year-end 2012. Read More
• Omthera Pharmaceuticals Inc., of Bedminster, N.J., completed enrollment in a pivotal, Phase III trial of Epanova, its triglyceride-lowering therapy. The trial, designated EVOLVE, is being carried out under a special protocol assessment with the FDA. Read More
